Method of producing pellets

专利摘要:
This invention relates to the pharmaceutical and pharmaceutical industry and concerns a process for the preparation of tablets. The goal is to simplify the way. A copolymer of M-vinylpyrrolidone and vinyl acetate with an N-vinylpyrrolidone content of 30-100 wt.% Is mixed with the active substance at a certain temperature and formed into tablets. 2 tab.
公开号:SU1731037A3
申请号:SU874202334
申请日:1987-04-10
公开日:1992-04-30
发明作者:Герц Ханс-Хельмут；Гюнтер Климеш Рошэ；Леммерхирт Клаус；Ланг Сигфрид；Саннер Аксель；Шпенглер Рейнхард
申请人:Басф Аг (Фирма)；
IPC主号:

专利说明:

This invention relates to the pharmaceutical and pharmaceutical industry and concerns a process for the preparation of tablets.
The purpose of the invention is to simplify the method.
The invention is illustrated by the following examples.
Example1.45ch. a copolymer with a K30 value consisting of 60% by weight of N-vinylpyrrolidone and 40% by weight of vinyl acetate, 5 parts of stearyl alcohol and 50 parts of theophylline in a molding machine are processed in drag. The processing temperature is 100 ° C. The resulting dragons are resistant to mechanical loads and do not wear out during transport and packaging. When tested in half-change-test Technologic Chemie, Weinheim, Deerfield Beach, Florida, Basel, in conjunction with the paddle-method, a full selection of the active beginning occurs in 6-8 hours.
PRI mme R 2. 50 hours of the copolymer of example 1 and 50 hours of theophylline is processed
in the injection molding machine into oblong tablets with a length of 1 cm. The processing temperature is 120 ° C. The tablets obtained by this method are also resistant to mechanical loads and release the active principle completely within 1-2 hours.
Example 47.5 parts, a copolymer with a K 30 value consisting of 60% by weight of N-vinylpyrrolidone and 40% by weight of vinyl acetate, 2.5 parts of cross-linked polyvinylpyrrolidone (PVP) as a swelling agent for tablets and 50 parts of theophylline are mixed in a two-way extruder and extracted. The temperature of the five sections is 120 ° C. The temperature of the mouthpiece 130 ° C. The obtained deformable tow with the help of a device is pressed into oblong tablets. They are resistant to mechanical stress. The release time of the active principle is 30-45 minutes.
PRI me R 4. 50 hours of a copolymer with a K 52 value consisting of 30% by weight of N-vinylpyrrolidone and 70% by weight of vinyl acetate, and 50
with
with
Xi
with about
; CJ XI
 CJ
h. theophylline is mixed in a double-screw extruder and extruded. The temperature of the five sections is 30, 60, 100, 100 and 120 ° C. The mouthpiece is also heated to 120 ° C. Analogously to example 3, a deformable harness is pressed into elongated tablets resistant to mechanical loads. The active principle is released completely within 8 hours.
EXAMPLE 5. 47.5 parts of a copolymer with a K 30 value consisting of 60% by weight of N-vinylpyrrolidone and 40% by weight of vinyl acetate, 2.5 parts of stearyl alcohol and 50 parts of theophylline are melted in the injection molding machine at 100 ° C and processed in dragel. The form is maintained at room temperature. The resulting drag are resistant to mechanical loads. The active principle is released completely within 6 hours.
In examples 6-11, a mixture of 50 May is used. % N VP Nopopolymer (PVP) with the sign K 12 - 60 and 50% by weight Theophylline, which is processed in a single-screw extruder at the indicated temperatures (see Table 1).
From the obtained tablets, the active principle is completely excreted (in artificial gastric juice) in the case of examples 6 and 7 in less than 30 minutes in the case of examples 8 and 9 in 1-2 hours, in the case of example 10 after more than 2 hours. Example 11 PVP contains 10% by weight of stearyl alcohol, and the release time of the active principle is 8 hours.
Examples 12-14. 36 parts of a copolymer with a K 30 value consisting of 60% by weight of N-vinylpyrrolidone and 40% by weight of vinyl acetate, 4 parts of stearyl alcohol, 40 parts of theophylline and 20 parts of starch (Example 12), lactose ( example 13), sucrose (example 14), is mixed in a six-section double-screw extruder and, analogously to example 1, is processed into tablets. The temperature of the individual sections is 90. 100.110, 120.130 and 130 ° C, the temperature of the mouthpiece is 135 ° C. The active principle is released from the tablets completely within 6 hours.
PRI me R 15. 50 hours of the copolymer according to examples 12-14 and 50 hours of lithium carbonate is processed into tablets in the car and
0
five
0
five
0
five
0
five
0
temperatures specified in examples 12-14. Tablets isolate the active principle completely (in artificial gastric juice) for 15–20 minutes.
PRI me R 16. 50 hours of the copolymer according to examples 12-14 and 50 verapamil are processed into tablets, as indicated in examples 12-14. The release time of the active principle is approximately 3 hours. The copolymers used for the preparation of solid solutions have the following compositions and K values:
A) 60 wt.% NVP and 40 wt.% Vinyl acetate; the value of K 33;
B) 100 wt% NVP; K value 30;
C) 100 wt.% NVP; the value of K 12;
D) 100 wt.% NVP; the value of K 17.
PRI me R 17. 3 parts of copolymer A and 1.5 parts of benzocaine are premixed in a mixer of the plowshare type and extruded using a simple, six-section extruder at the following section temperatures, counting towards the mouthpiece: 30, 30, 40, 50, 60, 70 ° C. The temperature of the mouthpiece is also 70 ° C. An extrudate consists of a solid solution which, according to the debaid diagram, shows no crystallinity. Similarly, in other examples (see Table 2) with the same result.
Examples 18, 19, 20 are repeated on the injection molding machine at a die temperature of 130 ° C. Tablets consisting of solid solutions are obtained.
Examples 21-50 are presented in table. 2
PRI me R 51. Vitamin C as an active principle is mixed in a double-screw extruder in a 1: 1 ratio with the following NVP polymers. The mixture is extruded at the indicated temperatures of sections 1-6 and the mouthpiece and processed into tablets using a calender.
a) a copolymer of 60 wt.% NVP and 40 wt.% vinyl acetate;
the value of K 33;
6) 90% by weight of copolymer aa) and 10% by weight of stearyl alcohol;
c) a homopolymer from NVP; the value of K 17.

141516
110120120
100100110
110120120
Mouthpiece 120 ° С 110 ° С 125 ° С
In all cases, the vitamin is released in water for 1-2 hours. With the described processing, it is retained 100%. In the form of tablets, vitamin is protected from prolonged exposure to light and oxygen.
The proposed method provides a simplification compared to the known one, since a number of stages of the method are excluded.

权利要求:
Claims (1)
[1]
The invention method for producing tablets by mixing the active substance with a copolymer of N-vinylpyrrolidone and vinyl acetate, and forming tablets, characterized in that, in order to simplify the process, a copolymer of N-vinylpyrrolidone and vinyl acetate is added with an N-vinylpyrrolidone content of 30-100 wt.% at 50-180 ° C.
Table 1
table 2
Note T1-T6- temperature sections 1 - b in ° C.
Continuation of table 2

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1731037A3|1992-04-30|Method of producing pellets

---

EP0544144B1|1995-06-14|Solid pharmaceutical retard form

---

EP0932393B1|2002-04-03|Solid foamed active substance preparations

---

AT6542U1|2003-12-29|TAMSULOSIN PELLETS AND METHOD FOR PRODUCING THE SAME

---

KR970702028A|1997-05-13|Sustained-Release Matrix Pellets and Method for Preparing Them

---

CZ291795B6|2003-05-14|Tablet formulation and process for preparing the formulation

---

JPH0198617A|1989-04-17|Copolymer by polymerization of glycolic acid and lactic acid

---

CA2071840A1|1991-05-07|Method for producing protein microspheres

---

DE102006007830A1|2007-08-30|Storage-stable oral dosage form of amoxicillin and clavulanic acid

---

CH629386A5|1982-04-30|FOR ORAL ADMINISTRATION PARTICULAR GRANULES OF A MEDICINAL PRODUCT.

---

DE19531684A1|1997-03-06|Process for the preparation of controlled release pharmaceutical preparations

---

EP0591363A1|1994-04-13|Pharmaceutical preparations containing torasemid

---

DE10341264A1|2005-03-24|Melt-formulated, multiparticulate oral dosage form

---

EP0615450B1|1997-01-22|Dimeticon pastilles

---

WO2005046634A2|2005-05-26|Gastric juice-resistant form of administration

---

DE2137213A1|1972-03-16|Plastic capsules and processes for their manufacture

---

EP1142571B1|2008-09-10|Method to produce solid creatine dosage forms and dosage forms thus obtained

---

EP0322086A3|1990-05-16|Accessories for use in apiculture

---

EP0391633A3|1991-07-24|Extrusion process of polyimide and polyimide pellet used for the process

---

SU971220A1|1982-11-07|Chewing gum and method of producing the same

---

EP0804152B1|1999-08-18|Lactulose lozenges

---

JPH01186823A|1989-07-26|Production of medicament-permeating substance

---

JPH01291752A|1989-11-24|Honey bee product increased in vitamins and its production

---

DE2164809A1|1972-07-20|Acrylonitrile polymer fibres - contg graft acrylic polymer material to raise hot wet modulus and dyeability

---

EP0998919A2|2000-05-10|Solid dosage form with copolymeric binder

同族专利:

---

公开号 | 公开日

---

DE3612212A1|1987-10-15|

---

NO170570B|1992-07-27|

---

FI871539A0|1987-04-08|

---

YU46534B|1993-11-16|

---

KR870009715A|1987-11-30|

---

CS268177B2|1990-03-14|

---

GR3005866T3|1993-06-07|

---

EP0240904B1|1992-07-01|

---

KR920003575B1|1992-05-04|

---

AU587897B2|1989-08-31|

---

CN1022666C|1993-11-10|

---

PT84661A|1987-05-01|

---

PT84661B|1989-11-30|

---

EP0240904A3|1988-11-30|

---

NO170570C|1992-11-04|

---

NO871513L|1987-10-12|

---

US4801460A|1989-01-31|

---

HUT43958A|1988-01-28|

---

MD374C2|1996-05-31|

---

CN87103409A|1987-12-09|

---

FI871539A|1987-10-12|

---

ES2037020T3|1993-06-16|

---

HU196132B|1988-10-28|

---

EP0240904A2|1987-10-14|

---

DE3780059D1|1992-08-06|

---

UA13038A1|1997-02-28|

---

NO871513D0|1987-04-10|

---

CS253287A2|1989-04-14|

---

JPH089551B2|1996-01-31|

---

JPS62242630A|1987-10-23|

---

FI87887C|1993-03-10|

---

AT77739T|1992-07-15|

---

CA1308353C|1992-10-06|

---

AU7141387A|1987-10-15|

---

FI87887B|1992-11-30|

---

YU59187A|1988-08-31|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

MD4399C1|2015-02-19|2016-09-30|Государственный Университет Молд0|Polymeric material with antibacterial properties|US3089818A|1960-06-02|1963-05-14|Baxter Laboratories Inc|Water dispersible antibiotics|

---

DE1137009B|1961-01-04|1962-09-27|Bayer Ag|Process for the preparation of an easily soluble streptomycin salt|

---

BE636865A|1962-08-31|

---

GB1348786A|1971-05-14|1974-03-20|Plessey Co Ltd|Apparatus and methods for assessing the length of a moving vehicle|

---

GB1388786A|1972-04-03|1975-03-26|Scherer Corp R P|Integral solid gel-lattice dosage form of high-moisture content|

---

CA1211892A|1982-09-20|1986-09-23|James R. Cho|Preparation of polyvinylpyrrolidone orvinylpyrrolidone/vinyl acetate copolymers of variousmolecular weights using a single initiator system|

---

YU43349B|1983-03-16|1989-06-30|Boehringer Ingelheim Ltd|Process for making a watersoluble, pharmaceutically acceptible dispersion of chlortalidone in solid state|

---

DE3312668A1|1983-04-08|1984-10-11|Basf Ag, 6700 Ludwigshafen|WATER-SOLUBLE POLYMERS WITH LOW HYGROSCOPY|

---

US4661521A|1984-04-30|1987-04-28|Mallinckrodt, Inc.|Direct tableting acetaminophen compositions|

---

US4631284A|1984-11-19|1986-12-23|Mallinckrodt, Inc.|Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom|

---

FR2581541B1|1985-05-09|1988-05-20|Rhone Poulenc Sante|NOVEL PHARMACEUTICAL COMPOSITIONS FOR THE EXTENDED RELEASE OF AN ACTIVE INGREDIENT AND THEIR PREPARATION METHOD|

---

EP0214092A1|1985-08-08|1987-03-11|Ciba-Geigy Ag|Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone|DE3612211A1|1986-04-11|1987-10-15|Basf Ag|CONTINUOUS TABLET METHOD|

---

US5051261A|1987-11-24|1991-09-24|Fmc Corporation|Method for preparing a solid sustained release form of a functionally active composition|

---

CA1334379C|1987-11-24|1995-02-14|James William Mcginity|Method for preparing a solid sustained release form of a functionally active composition|

---

DE3803482A1|1988-02-05|1989-08-17|Lohmann Therapie Syst Lts|FLOATING ORAL THERAPEUTIC SYSTEM|

---

DE3807895A1|1988-03-10|1989-09-21|Knoll Ag|PRODUCTS CONTAINING A CALCIUM ANTAGONIST AND A LIPID DOWNER|

---

DE3812567A1|1988-04-15|1989-10-26|Basf Ag|METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES|

---

DE3830353A1|1988-09-07|1990-03-15|Basf Ag|METHOD FOR THE CONTINUOUS PRODUCTION OF SOLID PHARMACEUTICAL FORMS|

---

DE3830355A1|1988-09-07|1990-03-15|Basf Ag|METHOD FOR PRODUCING PHARMACEUTICAL TABLETS|

---

WO1991007184A1|1989-11-08|1991-05-30|Gaf Chemicals Corporation|SUBSTANTIALLY ANHYDROUS COMPLEXES OF PVP and H2O¿2?|

---

PH26730A|1988-12-30|1992-09-28|Ciba Geigy Ag|Coated adhesive tablets|

---

US5310549A|1989-08-31|1994-05-10|Ecolab Inc.|Solid concentrate iodine composition|

---

US5008106A|1989-12-14|1991-04-16|Gaf Chemicals Corporation|Method for reducing the microbial content of surfaces with a microbiocidal, anhydrous complex of PVP-H2 O2|

---

IE63986B1|1989-12-30|1995-06-28|Akzo Nv|Pharmaceutical preparation for oral administration in fluid form|

---

FR2663818B1†|1990-06-29|1993-07-09|Rhone Poulenc Nutrition Animale|PROCESS FOR THE PREPARATION OF GRANULES OF ACTIVE PRINCIPLES BY EXTRUSION.|

---

DE4031881C2|1990-10-08|1994-02-24|Sanol Arznei Schwarz Gmbh|Solvent-free, oral sustained-release pharmaceutical preparation and process for its preparation|

---

TW212761B|1991-04-09|1993-09-11|Takeda Pharm Industry Co Ltd|

---

KR0182801B1|1991-04-16|1999-05-01|아만 히데아키|Method of manufacturing solid dispersion|

---

US5286497A|1991-05-20|1994-02-15|Carderm Capital L.P.|Diltiazem formulation|

---

US5326570A|1991-07-23|1994-07-05|Pharmavene, Inc.|Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine|

---

KR100243956B1|1991-09-06|2000-03-02|랄프 알. 팔로|Composition comprising a tramadol material and actaminophen for the treatment of pain|

---

WO1993007859A1|1991-10-23|1993-04-29|Warner-Lambert Company|Novel pharmaceutical pellets and process for their production|

---

DE4138513A1|1991-11-23|1993-05-27|Basf Ag|SOLID PHARMACEUTICAL RETARD FORM|

---

DE69222182T2|1991-12-18|1998-02-26|Warner Lambert Co|METHOD FOR PRODUCING A SOLID DISPERSION|

---

US5190749A|1992-01-13|1993-03-02|Isp Investments Inc.|Copolymers of vinyl pyrrolidone and a quaternary ammonium monomer complexed with H2 O2 in the form of free-flowing powders|

---

US5429825A|1992-06-26|1995-07-04|Mcneil-Ppc, Inc.|Rotomelt granulation|

---

TW246635B|1992-10-08|1995-05-01|Shell Internat Res Schappej B V|

---

KR100354702B1|1993-11-23|2002-12-28|유로-셀티크 소시에떼 아노뉨|Manufacturing method and sustained release composition of pharmaceutical composition|

---

US5891471A|1993-11-23|1999-04-06|Euro-Celtique, S.A.|Pharmaceutical multiparticulates|

---

NZ260408A|1993-05-10|1996-05-28|Euro Celtique Sa|Controlled release preparation comprising tramadol|

---

DE4316537A1|1993-05-18|1994-11-24|Basf Ag|Preparations in the form of solid solutions|

---

DE69432186T2|1993-11-18|2004-05-06|Nippon Shinyaku Co., Ltd.|METHOD FOR PRODUCING STABLE MEDICINAL PRODUCTS|

---

US5843480A|1994-03-14|1998-12-01|Euro-Celtique, S.A.|Controlled release diamorphine formulation|

---

DE4413350A1|1994-04-18|1995-10-19|Basf Ag|Retard matrix pellets and process for their production|

---

EP0691124A1|1994-07-07|1996-01-10|Sara Lee/DE N.V.|Mouth care products|

---

GB9422154D0|1994-11-03|1994-12-21|Euro Celtique Sa|Pharmaceutical compositions and method of producing the same|

---

US5965161A|1994-11-04|1999-10-12|Euro-Celtique, S.A.|Extruded multi-particulates|

---

US5871776A|1995-01-31|1999-02-16|Mehta; Atul M.|Controlled-release nifedipine|

---

DE19504832A1|1995-02-14|1996-08-22|Basf Ag|Solid drug preparations|

---

DE19509805A1|1995-03-21|1996-09-26|Basf Ag|Transparent, fast-release formulations of nonsteroidal analgesics|

---

DE19509806A1|1995-03-21|1996-09-26|Basf Ag|Storage stable dosage forms|

---

DE19511131A1|1995-03-27|1996-10-02|Basf Ag|Mechanically stable solid active substance preparation forms|

---

US5900425A|1995-05-02|1999-05-04|Bayer Aktiengesellschaft|Pharmaceutical preparations having controlled release of active compound and processes for their preparation|

---

BE1009375A6|1995-05-29|1997-02-04|Picanol Nv|Edge device for looms.|

---

US20060280774A1|1995-06-02|2006-12-14|Allergan, Inc.|Compositions and methods for treating glaucoma|

---

US5869079A|1995-06-02|1999-02-09|Oculex Pharmaceuticals, Inc.|Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents|

---

EP0952770A4|1995-09-07|1999-12-22|Fuisz Technologies Ltd|System for rendering substantially non-dissoluble bio-affecting agents bio-available|

---

DE19539361A1|1995-10-23|1997-04-24|Basf Ag|Process for the preparation of multilayer, solid pharmaceutical forms for oral or rectal administration|

---

DE19602206A1|1996-01-23|1997-07-24|Basf Ag|Preparations of nonsteroidal analgesics|

---

US6090419A|1996-05-02|2000-07-18|Mccormick & Company, Inc.|Salt compositions and method of preparation|

---

DE19629040A1|1996-07-19|1998-01-22|Basf Ag|Pharmaceutical forms containing plant extract|

---

DE19629753A1|1996-07-23|1998-01-29|Basf Ag|Process for the production of solid dosage forms|

---

DE19635676A1|1996-09-03|1998-03-05|Basf Ag|Solid foamed active ingredient preparations|

---

HRP970485A2|1996-09-13|1998-08-31|Joerg Rosenberg|Process for producing solid pharmaceutical forms|

---

DE19710213A1|1997-03-12|1998-09-17|Basf Ag|Process for the manufacture of solid combination dosage forms|

---

DE19753298A1|1997-12-01|1999-06-02|Basf Ag|Process for the preparation of solid dosage forms|

---

DE19812688A1|1998-03-23|1999-09-30|Basf Ag|Solid dosage forms useful for slow release of drugs, fragrances, plant-treating agents, animal feed additives and food additives|

---

DE19814730A1|1998-04-02|1999-10-07|Basf Ag|Pharmaceutical and cosmetic compositions with matrix containing N-vinyllactam or N-vinylamine based copolymer|

---

NZ508421A|1998-04-30|2003-01-31|Basf Ag|Crop protection formulations with delayed release of active ingredient|

---

US6197347B1|1998-06-29|2001-03-06|Andrx Pharmaceuticals, Inc.|Oral dosage for the controlled release of analgesic|

---

DE19840256A1|1998-09-03|2000-03-09|Basf Ag|Widely applicable, continuous method for preparing coated solid dosage forms, comprises extruding mixture of drug and thermoplastic binder then applying coating composition in liquid or vapor form|

---

DE19841244A1|1998-09-09|2000-03-16|Knoll Ag|Method and device for making tablets|

---

DE19842914A1|1998-09-18|2000-03-23|Basf Ag|Test system to characterize the compatibility of biologically active substances and polyvinylpyrrolidone|

---

DE19842753A1|1998-09-18|2000-03-23|Bayer Ag|Multiple-unit retard oral dosage formulation having controlled release independent of agitation and food effect, containing particles of combination of drug and hydroxypropyl cellulose|

---

DE19843904A1|1998-09-24|2000-03-30|Basf Ag|Solid dosage form for prolonged slow release of e.g. drugs, plant treatment agents, or food or feed additives, containing copolymer of N-vinyl-lactam, methyl methacrylate and further monomer as binder|

---

DE19843903A1|1998-09-24|2000-03-30|Basf Ag|Solid dosage form for prolonged slow release of e.g. drugs, plant treatment agents or food or feed additives, containing copolymer of N-vinyl-lactam and methyl methacrylate as binder|

---

US20020006438A1|1998-09-25|2002-01-17|Benjamin Oshlack|Sustained release hydromorphone formulations exhibiting bimodal characteristics|

---

DE19847618A1|1998-10-15|2000-04-20|Basf Ag|Production of solid dosage forms, used for e.g. pharmaceuticals or insecticides, by preparation of plastic mixture from polymeric binder and active agent under controlled conditions|

---

WO2000028816A1|1998-11-12|2000-05-25|Basf Aktiengesellschaft|Plant protection agents in tablet form|

---

DE19853985A1|1998-11-23|2000-05-25|Basf Ag|Producing solid dosage form, using molding calender of two cylinders with specific surface structures, avoids problems of misalignment of upper and lower halves of the product|

---

CA2355077C|1998-12-16|2009-05-26|Aventis Pharmaceuticals Inc.|Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same|

---

US6455526B1|1998-12-16|2002-09-24|Aventis Pharmaceuticals, Inc.|Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same|

---

DE19901383A1|1999-01-15|2000-07-20|Knoll Ag|Process for the preparation of different solid dosage forms|

---

DE19913692A1|1999-03-25|2000-09-28|Basf Ag|Mechanically stable pharmaceutical dosage forms containing liquid or semi-solid surface-active substances|

---

DE19918325A1|1999-04-22|2000-10-26|Euro Celtique Sa|Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives|

---

DE19934610A1|1999-07-23|2001-01-25|Bayer Ag|Rapid-release extrudates containing low viscosity hydroxypropylcellulose, useful for formulating plant protecting agents and oral pharmaceutical and veterinary compositions|

---

DE19943501A1|1999-09-10|2001-03-15|Basf Ag|Underwater granulation of melts containing active ingredients|

---

DE19945982A1|1999-09-24|2001-03-29|Knoll Ag|Velocity-determined particles|

---

US6331313B1|1999-10-22|2001-12-18|Oculex Pharmaceticals, Inc.|Controlled-release biocompatible ocular drug delivery implant devices and methods|

---

EP1175205B1|1999-11-12|2006-06-14|Abbott Laboratories|Solid dispersion comprising ritonavir, fenofibrate or griseofulvin|

---

US7364752B1|1999-11-12|2008-04-29|Abbott Laboratories|Solid dispersion pharamaceutical formulations|

---

US6544553B1|1999-12-28|2003-04-08|Watson Pharmaceuticals, Inc.|Dosage forms and methods for oral delivery of progesterone|

---

DE10017102A1|2000-04-06|2001-10-11|Basf Ag|Process for the manufacture of solid creatine dosage forms and dosage forms obtainable thereby|

---

US6635277B2|2000-04-12|2003-10-21|Wockhardt Limited|Composition for pulsatile delivery of diltiazem and process of manufacture|

---

DE10026698A1|2000-05-30|2001-12-06|Basf Ag|Self-emulsifying active ingredient formulation and use of this formulation|

---

DE10029201A1|2000-06-19|2001-12-20|Basf Ag|Retarded release oral dosage form, obtained by granulating mixture containing active agent and polyvinyl acetate-polyvinyl pyrrolidone mixture below the melting temperature|

---

US6726918B1|2000-07-05|2004-04-27|Oculex Pharmaceuticals, Inc.|Methods for treating inflammation-mediated conditions of the eye|

---

AR038375A1|2002-02-01|2005-01-12|Pfizer Prod Inc|PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE PROTEIN OF TRANSFER OF ESTERES DE COLESTERILO|

---

US6500457B1|2000-08-14|2002-12-31|Peirce Management, Llc|Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent|

---

DE10046541A1|2000-09-19|2002-03-28|Knoll Ag|Oral dosage form useful as nutritional supplement or medicament comprises solid dispersion of ubiquinone in thermoplastic matrix|

---

EP1339438B1|2000-11-29|2005-10-19|Allergan Inc.|Preventing transplant rejection in the eye|

---

US20050175687A1|2001-01-30|2005-08-11|Mcallister Stephen M.|Pharmaceutical formulations|

---

US7842308B2|2001-01-30|2010-11-30|Smithkline Beecham Limited|Pharmaceutical formulation|

---

US7883721B2|2001-01-30|2011-02-08|Smithkline Beecham Limited|Pharmaceutical formulation|

---

GB0102342D0|2001-01-30|2001-03-14|Smithkline Beecham Plc|Pharmaceutical formulation|

---

GB0113841D0|2001-06-07|2001-08-01|Boots Co Plc|Therapeutic agents|

---

CA2471948A1|2002-01-03|2003-07-17|Smithkline Beecham Corporation|Novel pharmaceutical dosage forms and method for producing same|

---

KR20040083493A|2002-02-01|2004-10-02|화이자 프로덕츠 인크.|Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor|

---

US8128957B1|2002-02-21|2012-03-06|Valeant InternationalSrl|Modified release compositions of at least one form of tramadol|

---

US20050182056A9|2002-02-21|2005-08-18|Seth Pawan|Modified release formulations of at least one form of tramadol|

---

AU2003218127B2|2002-03-11|2007-07-12|Alcon, Inc.|Implantable drug delivery system|

---

DE10213242A1|2002-03-25|2003-10-16|Abbott Gmbh & Co Kg|Test system for evaluating the compatibility of biologically active substances with copolymers|

---

BR0313428A|2002-08-12|2005-06-28|Pfizer Prod Inc|Pharmaceutical compositions of semi-ordered drugs and polymers|

---

AU2003272601B2|2002-09-20|2009-05-07|Alpharma Pharmaceuticals, Llc|Sustained-release opioid formulations and methods of use|

---

DE10247037A1|2002-10-09|2004-04-22|Abbott Gmbh & Co. Kg|Solid, rapid release dosage form, especially for sparingly soluble drugs, obtained by forming and cooling softened, shapable mixture of crosslinked non-thermoplastic carrier, adjuvant and active agent|

---

CN100473378C|2002-12-17|2009-04-01|阿伯特有限及两合公司|Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof|

---

US20080051411A1|2002-12-17|2008-02-28|Cink Russell D|Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof|

---

US20050048099A1|2003-01-09|2005-03-03|Allergan, Inc.|Ocular implant made by a double extrusion process|

---

WO2004069180A2|2003-01-31|2004-08-19|Smithkline Beecham Corporation|Solid dispersion compositions|

---

EP1594468A2|2003-02-03|2005-11-16|Novartis AG|Process for preparing a solid dispersion pharmaceutical product|

---

US20050100608A1|2003-02-21|2005-05-12|Watson Pharmaceuticals, Inc.|Testosterone oral dosage formulations and associated methods|

---

US20040219210A1|2003-05-01|2004-11-04|Jian-Hwa Guo|Controlled release solid dosage nifedipine formulations|

---

WO2005003192A1|2003-06-26|2005-01-13|Symyx Technologies, Inc.|Synthesis of photoresist polymers|

---

TW200526274A|2003-07-21|2005-08-16|Smithkline Beecham Plc|Pharmaceutical formulations|

---

US8377952B2|2003-08-28|2013-02-19|Abbott Laboratories|Solid pharmaceutical dosage formulation|

---

US8025899B2|2003-08-28|2011-09-27|Abbott Laboratories|Solid pharmaceutical dosage form|

---

WO2005027864A1|2003-09-19|2005-03-31|Symyx Technologies, Inc.|Materials for enhanced delivery of hydrophilic active agents in personal care formulations|

---

JP2007511559A|2003-11-18|2007-05-10|ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング|Solid pharmaceutical formulation|

---

TWI350762B|2004-02-12|2011-10-21|Euro Celtique Sa|Particulates|

---

GB0403098D0|2004-02-12|2004-03-17|Euro Celtique Sa|Extrusion|

---

PE20060003A1|2004-03-12|2006-03-01|Smithkline Beecham Plc|POLYMERIC PHARMACEUTICAL FORMULATION FOR INJECTION MOLDING|

---

US20050244469A1|2004-04-30|2005-11-03|Allergan, Inc.|Extended therapeutic effect ocular implant treatments|

---

US20070237823A1|2004-05-04|2007-10-11|Thomas Bock|Solid Pharmaceutical Form Comprising and Ltb4 Antagonist|

---

PL1748762T3|2004-05-28|2014-05-30|Abbvie Deutschland|Dosage form obtainable from a mixture of powders containing an inorganic pigment|

---

FR2875409B1|2004-09-17|2010-05-07|Sanofi Aventis|PHARMACEUTICAL COMPOSITION COMPRISING A SOLID POLYMERIC MATRIX DISPERSION COMPRISING A CONTINUOUS PHASE OF POLYDEXTROSE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE|

---

AU2006244214A1|2005-05-10|2006-11-16|Novartis Ag|Modified release famciclovir pharmaceutical compositions|

---

NZ561375A|2005-06-27|2011-06-30|Biovail Lab Int Srl|Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound|

---

AT476997T|2005-07-05|2010-08-15|Abbott Gmbh & Co Kg|COMPOSITION AND DOSAGE FORM WITH A SOLID OR HALF-RESISTANT MATRIX|

---

US8486456B2|2005-08-08|2013-07-16|Abbott Gmbh & Co., Kg|Itraconazole compositions with improved bioavailability|

---

DK1912626T3|2005-08-08|2016-08-01|Abbvie Deutschland|Dosage forms with improved bioavailability|

---

US7534381B2|2005-09-14|2009-05-19|Isp Investments Inc.|Process and apparatus for forming agglomerates of a powder composition of an active and binder|

---

US20070178138A1|2006-02-01|2007-08-02|Allergan, Inc.|Biodegradable non-opthalmic implants and related methods|

---

EP1832281A1|2006-03-10|2007-09-12|Abbott GmbH & Co. KG|Process for producing a solid dispersion of an active ingredient|

---

US20070298073A1|2006-06-23|2007-12-27|Allergan, Inc.|Steroid-containing sustained release intraocular implants and related methods|

---

US8802128B2|2006-06-23|2014-08-12|Allergan, Inc.|Steroid-containing sustained release intraocular implants and related methods|

---

US20080057122A1|2006-08-31|2008-03-06|Aaipharma Inc.|Acetaminophen pharmaceutical compositions|

---

US20080181948A1|2006-11-15|2008-07-31|Abbott Laboratories|Solid pharmaceutical dosage formulations|

---

US20080145405A1|2006-12-15|2008-06-19|Kunzler Jay F|Drug delivery devices|

---

US7607596B1|2007-03-07|2009-10-27|Exxpharma, LLC|Process for enhancing the solubility of poorly soluble drugs|

---

EP2219624A2|2007-11-08|2010-08-25|Glaxo Group Limited|Pharmaceutical formulations|

---

US20090246276A1|2008-01-28|2009-10-01|Graham Jackson|Pharmaceutical Compositions|

---

WO2009150228A2|2008-06-13|2009-12-17|Glaxo Group Limited|Pharmaceutical formulations|

---

US20100003322A1|2008-07-03|2010-01-07|Lai Felix S|Enteric coated hydrophobic matrix formulation|

---

WO2010041051A1|2008-10-07|2010-04-15|Astrazeneca Uk Limited|Pharmaceutical formulation 514|

---

US9789065B2|2008-10-07|2017-10-17|Basf Se|Process for producing oral dosage forms with controlled release|

---

US20120168987A1|2009-09-18|2012-07-05|Basf Se|Method For Producing Preparations Of Substances With Low Solubility In Water|

---

EP2536393B1|2010-02-18|2014-04-16|AbbVie Deutschland GmbH & Co KG|Test solvent for evaluating the compatibility of biologically active substances and graft copolymers|

---

EP2463327A3|2010-12-10|2015-06-03|Basf Se|Method for producing granulates containing at least one water-soluble component|

---

DK2654731T3|2010-12-23|2016-11-14|Abbvie Deutschland|SOLID Retard-FORMULATIONS BASED ON SOLID DISPERSIONS|

---

CA2937315A1|2014-02-05|2015-08-13|Merck Sharp & Dohme Corp.|Tablet formulation for cgrp-active compounds|

---

CN104666084B|2014-11-27|2018-07-13|天津坤健生物制药有限公司|A method of it improves and delays controlled release coat piece dissolution rate stability|

---

AU2017336537B2|2016-09-27|2020-02-27|L.P. Brown Company, Inc.|Harvested bale wrapping material sheets|

---

WO2019087084A1|2017-11-02|2019-05-09|Eman Biodiscoveries Sd. Bhd.|Extract of orthosiphon stamineus, formulations, and uses thereof|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

DE19863612212|DE3612212A1|1986-04-11|1986-04-11|METHOD FOR PRODUCING SOLID PHARMACEUTICAL FORMS|LTRP532A| LT2085B|1986-04-11|1993-05-06|THE TALK OF THE TABLET|

---

LV930427A| LV5176A3|1986-04-11|1993-05-27|Tables manufacturing tolerance|